Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -3676.90% is 402% below its 1-year average of -731.86%, near the low end of its 1-year range (-3676.90%–-232.72%).
360.65% below its 12-month average of -798.20%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2020 (2020-06-30): -2031.88%.
EBITDA MARGIN
-3676.90%
EBITDA MARGIN AVG TTM
-798.20%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-360.65%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
ALX Oncology Holdings Inc.
Market Cap
$160.80M
EBITDA Margin
-3676.90%
TTM Avg
-798.20%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$156.62M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$165.46M
EBITDA Margin
-416.41%
TTM Avg
-228.13%
3Y Avg
-163.44%
5Y Avg
-116.60%
Market Cap
$155.62M
EBITDA Margin
-48812.58%
TTM Avg
-48812.58%
3Y Avg
-48812.58%
5Y Avg
-48812.58%
Market Cap
$154.76M
EBITDA Margin
-47.00%
TTM Avg
-68.63%
3Y Avg
-61.93%
5Y Avg
-48.63%
Market Cap
$153.56M
EBITDA Margin
-0.19%
TTM Avg
-1.66%
3Y Avg
-11.02%
5Y Avg
-42.72%
Market Cap
$172.65M
EBITDA Margin
-138.09%
TTM Avg
-113.30%
3Y Avg
-81.67%
5Y Avg
-67.39%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ALX Oncology Holdings Inc. (ALXO) | $160.80M | -3676.90% | -798.20% | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $159.74M | -2.74% | -4.58% | -13.60% | -7.28% |
| Anavex Life Sciences Corp. (AVXL)vs › | $158.01M | N/A | N/A | N/A | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $156.62M | N/A | N/A | N/A | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $165.46M | -416.41% | -228.13% | -163.44% | -116.60% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $155.62M | -48812.58% | -48812.58% | -48812.58% | -48812.58% |
| Codexis, Inc. (CDXS)vs › | $154.76M | -47.00% | -68.63% | -61.93% | -48.63% |
| LifeMD, Inc. (LFMDP)vs › | $153.56M | -0.19% | -1.66% | -11.02% | -42.72% |
| MediWound Ltd. (MDWD)vs › | $172.65M | -138.09% | -113.30% | -81.67% | -67.39% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $148.07M | -550.97% | -275.49% | -275.49% | -275.49% |
Gross Margin
0.0%
EBITDA Margin
-3676.9%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2020-06-30 | -2031.88% |
| 2020-03-31 | -783.05% |
| 2019-12-31 | -628.28% |
| 2019-09-30 | -232.72% |
| 2019-06-30 | -315.06% |
| 2019-03-31 | -400.19% |
